Gilead Sciences (GILD) Tops Q3 EPS by 38c, Offers Guidance

Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.29, $0.38 better than the analyst estimate of $1.91. Revenue for the quarter came in at $7.1 billion versus the consensus estimate of $6.81 billion.

GUIDANCE:

Gilead Sciences sees FY2023 EPS of $6.65-$6.85, versus the consensus of $6.25. Gilead Sciences sees FY2023 revenue of $26.7-26.9 billion, versus the consensus of $25.3 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Gilead and PAHO agree on lenacapavir HIV prevention access in Americas
• Lennar Corp. (LEN) Misses Q3 EPS by 10c